Axcelis Technologies Inc. | Mutual Funds

Mutual Funds that own Axcelis Technologies Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
PRIMECAP Odyssey Aggressive Growth Fund
2,510,000
7.76%
-129,500
0.45%
06/30/2018
iShares Core S&P Small Cap ETF
1,791,349
5.54%
507
0.08%
09/06/2018
Vanguard Total Stock Market Index Fund
789,690
2.44%
0
0%
07/31/2018
iShares Russell 2000 ETF
670,997
2.06%
-357
0.03%
09/06/2018
Wells Fargo Advantage Small Company Growth Portfolio
597,166
1.85%
0
0.49%
07/31/2018
iShares S&P Small Cap 600 Growth ETF
557,079
1.72%
799
0.15%
09/06/2018
Government Pension Fund - Global (The)
543,806
1.68%
400,746
0%
12/31/2017
Parvest - Equity USA Small Cap
487,791
1.51%
176,993
1.02%
07/31/2018
DFA US Small Cap Portfolio
475,674
1.47%
0
0.04%
04/30/2018
Vanguard Extended Market Index Fund
427,836
1.32%
900
0.01%
07/31/2018

About Axcelis Technologies

View Profile
Address
108 Cherry Hill Drive
Beverly Massachusetts 01915
United States
Employees -
Website http://www.axcelis.com
Updated 07/08/2019
Axcelis Technologies, Inc. engages in the design, manufacture and service of dry strip, ion implantation and other processing equipment used in the fabrication of semiconductor chips. The company provides service and support, including spare parts, equipment upgrades, maintenance services and customer training. Its products include Purion H, which is next generation single wafer high current implanter; Optima HDx, is designed to maximize beam current, minimize beam setup time and deliver productive process across the applications space; Purion XE, is next generation single wafer high energy implanter, it is the second tool in the expanding family of Purion ion implanters; Optima XEx, includes implant energies matched to meet the changing needs of today's advanced device manufacturing; Paradigm XE, offers implant energies matched to meet the changing needs of advanced logic and memory manufacturing; and Purion M, is a low energy, medium current ion implanter for all channel engineering applications in the low dose and mid dose regimes.